Product Details:
| Strength | 2 mg |
| Compostion | Pomalidomide |
| Prescription/Non prescription | Prescription |
| Brand | Pomide |
| Form Type | Capsules |
| Manufactured By | Natco |
| Packaging Size | 21 Capsules |
| Packaging Type | Box |
Pomalidomide Capsules 2mg are advanced oral chemotherapy and immunomodulatory agents primarily used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. These capsules are typically prescribed for adults who have received at least two prior therapies, including lenalidomide and bortezomib, and whose disease has progressed despite previous treatments. Pomalidomide works by stimulating the immune system to attack cancer cells, inhibiting the growth and survival of myeloma cells, and blocking the formation of new blood vessels that supply nutrients to tumors, thereby slowing the progression of the disease. In clinical practice, Pomalidomide Capsules 2mg are often used in combination with dexamethasone, an anti-inflammatory medication, to enhance their anti-cancer effects. In addition to multiple myeloma, pomalidomide is also indicated for the treatment of Kaposi’s sarcoma in patients with AIDS who have not responded to highly active antiretroviral therapy (HAART), as well as in HIV-negative patients with Kaposi’s sarcoma. Common side effects of Pomalidomide Capsules 2mg can include tiredness, nausea, diarrhea, constipation, back and bone pain, dizziness, respiratory infections, muscle weakness, numbness or tingling sensations, and low blood cell counts, so regular monitoring by a healthcare professional is essential during treatment. Due to the risk of severe birth defects, pomalidomide is available only under a restricted distribution program, and strict birth control measures must be followed during therapy. Pomalidomide Capsules 2mg should not be used in children or adolescents under 18 years of age and are contraindicated in pregnancy. Patients should inform their doctor of any existing medical conditions, ongoing medications, or allergies before starting treatment. These capsules are available by prescription only and should be taken exactly as directed by the oncologist, with careful adherence to dosage and monitoring protocols to ensure safety and maximize therapeutic benefit in the management of relapsed or refractory multiple myeloma and certain cases of Kaposi’s sarcoma.